世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い



欧州の不妊症検査と治療市場予測 2019-2027年

EUROPE INFERTILITY TESTING AND TREATMENT MARKET FORECAST 2019-2027

 

出版社 出版日電子媒体価格ページ数
Inkwood Research
インクウッドリサーチ
2019年4月 US$ 1,250
シングルユーザライセンス(印刷不可PDF)
107p

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

サマリー

この調査レポートは欧州の不妊症検査と治療市場を分析・予測したInkwood Researchの市場調査報告書です。

Overview

KEY FINDINGS

There are various reasons for infertility, which include physiological, genetically induced disorders and at times may be self-induced as in the case of contraceptive surgeries. Infertility treatment is a multi-billion dollar industry. The key factors driving the market include raising awareness among couples about various infertility treatments, low-cost treatment options and an increase in new options for infertility treatment such as surrogacy.
The market is expected to lead throughout the forecast period of 2019-2027 by proliferating at a CAGR of 6.12%. The market is expected to lead throughout the forecast period of 2019-2027.
MARKET INSIGHTS
Medical tourism has been a key enabler for the growth of the infertility testing and treatment market. Fertility tourism for IVF, donor sperm, surrogate mothers and other infertility treatments are increasing due to a decrease in domestic supply and stringent government regulations in Europe.
The economies of the United Kingdom, Germany, France, Russia, and the Nordics are the major contributors to the market growth in Europe. The Nordic region has been a destination for fertility tourism for most couples from Europe, North America, Kenya, and Hong Kong. German infertility testing and treatment is the second fastest growing market in Europe. Increasing success rates of the IVF treatments within the region has led to significant growth in this market.
COMPETITIVE INSIGHTS
The major market players mentioned in the report are Vitrolife AB, Endo Pharmaceuticals, Merck, The Cooper Companies, Inc., Irvine Scientific, Genea, Thermo Fisher Scientific Inc., Quest Diagnostic, Ovascience, Halotech DNA, Origio, Andrology Solutions, Ferring Pharmaceuticals, Esco Micro PTE. Ltd., and Progyny.



目次

Table of Contents

1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP-DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2.

KEY FINDINGS

3.2.1. EUROPE IS THE LARGEST MARKET
3.2.2. IVF DOMINATES THE FEMALE TREATMENT MARKET
3.2.3. OXIDATIVE STRESS ANALYSIS IS THE FASTEST GROWING MALE INFERTILITY TESTING MARKET
4. MARKET OVERVIEW
4.1. MARKET DEFINITION
4.2. MARKET DRIVERS AND IMPACT
4.2.1. RISE IN INFERTILITY AND TREATMENT AWARENESS
4.2.2. MEDICAL TOURISM FOR FERTILITY TREATMENTS
4.2.3. SURROGACY LAWS ARE GETTING MORE DEFINED
4.2.4. HEALTHCARE ADVANCES HAVE FINETUNED FERTILITY TREATMENT
4.2.5. INCREASING EFFECTIVENESS OF TREATMENTS
4.2.6. HEALTHIER DONOR EGGS
4.2.7. INTRODUCTION OF NEW TESTING DEVICES
4.3. MARKET RESTRAINTS AND IMPACT
4.3.1. TREATMENT PROCEDURE OUT OF REACH TO MANY DUE TO COSTS INVOLVED
4.3.2. COUNTRY-WISE REGULATORY ISSUES
4.4. MARKET OPPORTUNITIES
4.4.1. REDUCING THE COST OF TREATMENT TO MAKE IT MORE ACCESSIBLE
4.4.2. IVF ATTRACTING INVESTMENTS FROM PRIVATE EQUITY INVESTORS
4.4.3. DIY TESTING INCREASING ACCESS AND REDUCING COST
4.5. MARKET CHALLENGES
4.5.1. INFERTILITY CONSIDERED A SOCIAL TABOO AMONGST MEN
4.5.2. PERILS OF MULTIPLE PREGNANCIES
4.5.3. TRADITIONAL TREATMENTS USED WIDELY AS AN ALTERNATIVE FOR INFERTILITY TREATMENTS
4.5.3.1. DIET AND SUPPLEMENTS
4.5.3.2. ACUPUNCTURE
4.5.3.3. THERAPY
4.5.3.4. QIGONG
5. INFERTILITY CAUSES
5.1. CAUSES OF MALE INFERTILITY
5.1.1. ABNORMALITY IN THE SPERM
5.1.2. ENVIRONMENTAL FACTORS
5.1.3. POOR HEALTH AND LIFESTYLE
5.2. CAUSES OF FEMALE INFERTILITY
5.2.1. OVULATION DISORDERS
5.2.2. DAMAGE TO FALLOPIAN TUBES
5.3. MORAL QUESTIONS
6. MALE INFERTILITY TESTING AND TREATMENT MARKET 2019-2027 ($ MILLION)
6.1. MARKET BY MALE INFERTILITY TESTING
6.1.1. DNA FRAGMENTATION
6.1.2. OXIDATIVE STRESS ANALYSIS
6.1.3. SPERM PENETRATION ASSAY
6.1.4. COMPUTER ASSISTED SEMEN ANALYSIS (CASA)
6.1.5. SPERM AGGLUTINATION
6.1.6. MICROSCOPIC EXAMINATION
6.1.7. OTHERS
6.2. MARKET BY MALE INFERTILITY TREATMENT
6.2.1. VASOVASOSTOMY AND VASOEPIDIDYMOSTOMY (VASECTOMY REVERSAL)
6.2.2. SPERM RETRIEVAL TREATMENT
6.2.3. MICROSURGICAL SPERM ASPIRATION (MESA)
6.2.4. TESTICULAR SPERM EXTRACTION (TESE)
6.2.5. VARICOCELE REPAIRS
6.2.6. ASSISTED REPRODUCTIVE TECHNIQUES (ART)
6.2.7. INTRAUTERINE INSEMINATION (IUI)
6.2.8. IN VITRO FERTILIZATION (IVF)
6.2.9. INTRACYTOPLASMIC SPERM INJECTION (ICSI)
7. FEMALE INFERTILITY TESTING AND TREATMENT MARKET 2019-2027 ($ MILLION)
7.1. MARKET BY FEMALE INFERTILITY TESTING
7.1.1. OVULATION TESTING
7.1.2. HYSTEROSALPINGOGRAPHY
7.1.3. LAPAROSCOPY
7.1.4. TRANSVAGINAL ULTRASOUND
7.1.5. OVARIAN RESERVE TESTING
7.1.6. HORMONAL LEVEL TESTING
7.1.7. OTHERS (GENETIC TESTING)
7.2. MARKET BY FEMALE INFERTILITY TREATMENT
7.2.1. IN VITRO FERTILIZATION
7.2.2. INTRAUTERINE INSEMINATION (IUI)
7.2.3. DRUG AND HORMONE THERAPIES
8. EUROPE INFERTILITY TESTING AND TREATMENT MARKET BY END-USERS 2019-2027 ($ MILLION)
8.1. FERTILITY AND SURGICAL CENTERS
8.2. HOSPITALS AND RESEARCH LABORATORIES
8.3. CRYOBANKS
9. KEY ANALYTICS
9.1. PORTER’S 5 FORCE MODEL
9.1.1. THREAT OF NEW ENTRANTS
9.1.2. THREAT OF SUBSTITUTE PRODUCTS
9.1.3. BARGAINING POWER OF BUYERS
9.1.4. BARGAINING POWER OF SUPPLIERS
9.1.5. INTENSITY OF COMPETITIVE RIVALRY
9.2. VALUE CHAIN ANALYSIS
9.2.1. RAW MATERIAL PROCUREMENT
9.2.2. MANUFACTURING
9.2.3. SUPPLY LOGISTICS
9.2.4. DISTRIBUTION CHANNELS
9.2.5. END-USERS
9.3. KEY BUYING CRITERIA
9.3.1. TREATMENT OPTIONS
9.3.2. QUALITY OF MEDICAL PROCEDURES
9.3.3. PRICE OF TREATMENTS
9.3.4. SHIFT TOWARDS MEDICAL TOURISM
9.3.5. REIMBURSEMENT
9.4. REGULATORY FRAMEWORK
9.5. VENDOR LANDSCAPE
9.6. OPPORTUNITY MATRIX
10. EUROPE INFERTILITY TESTING AND TREATMENT MARKET COUNTRY ANALYSIS 2019-2027 ($ MILLION)
10.1. UK
10.2. GERMANY
10.3. FRANCE
10.4. NORDICS
10.5. RUSSIA
11. COMPANY PROFILES
11.1. ANDROLOGY SOLUTIONS
11.2. ENDO PHARMACEUTICALS
11.3. PROGYNY
11.4. FERRING PHARMACEUTICALS
11.5. GENEA
11.6. HALOTECH DNA
11.7. IRVINE SCIENTIFIC
11.8. MERCK
11.9. ORIGIO
11.10. OVASCIENCE
11.11. VITROLIFE AB
11.12. THERMO FISHER SCIENTIFIC INC.
11.13. THE COOPER COMPANIES, INC.
11.14. QUEST DIAGNOSTIC
11.15. ESCO MICRO PTE. LTD.

LIST OF TABLES
TABLE 1 EUROPE INFERTILITY TESTING AND TREATMENT MARKET BY GENDER 2019-2027 ($ MILLION)
TABLE 2 AVERAGE COST COMPARISON OF INFERTILITY TREATMENTS
TABLE 3 EUROPE MALE INFERTILITY TESTING AND TREATMENT MARKET 2019-2027 ($ MILLION)
TABLE 4 EUROPE MALE INFERTILITY TESTING MARKET 2019-2027 ($ MILLION)
TABLE 5 PROS AND CONS OF DNA SHARING METHODS
TABLE 6 EUROPE FEMALE INFERTILITY TESTING AND TREATMENT MARKET 2019-2027 ($ MILLION)
TABLE 7 EUROPE FEMALE INFERTILITY TESTING MARKET 2019-2027 ($ MILLION)
TABLE 8 EUROPE FEMALE INFERTILITY TREATMENT MARKET 2019-2027 ($ MILLION)
TABLE 9 AVERAGE COST OF SOME INFERTILITY TREATMENTS
TABLE 10 SOME COMMON DRUG THERAPIES
TABLE 11 EUROPE INFERTILITY TESTING AND TREATMENT MARKET BY END-USERS 2019-2027 ($ MILLION)
TABLE 12 EUROPE INFERTILITY TESTING AND TREATMENT MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 13 COST OF IVF IN RUSSIA


LIST OF FIGURES
FIGURE 1 EUROPE INFERTILITY TESTING AND TREATMENT MARKET 2019-2027 ($ MILLION)
FIGURE 2 MAJOR FERTILITY TREATMENT DESTINATION RANKING
FIGURE 3 CLINICAL ALGORITHM FOR THE EVALUATION OF INFERTILE WOMAN
FIGURE 4 RATE OF MULTIPLE DELIVERIES
FIGURE 5 CAUSES OF INFERTILITY
FIGURE 6 CAUSES OF INFERTILITY BASED ON GENDER
FIGURE 7 CAUSES OF SPERM DNA FRAGMENTATION
FIGURE 8 UK INFERTILITY TESTING AND TREATMENT MARKET 2019-2027 ($ MILLION)
FIGURE 9 FERTILITY TREATMENT IN 2014
FIGURE 10 GERMANY INFERTILITY TESTING AND TREATMENT MARKET 2019-2027 ($ MILLION)
FIGURE 11 FRANCE INFERTILITY TESTING AND TREATMENT MARKET 2019-2027 ($ MILLION)
FIGURE 12 NORDICS INFERTILITY TESTING AND TREATMENT MARKET 2019-2027 ($ MILLION)
FIGURE 13 RUSSIA INFERTILITY TESTING AND TREATMENT MARKET 2019-2027 ($ MILLION)

List of Tables

LIST OF TABLES
TABLE 1 EUROPE INFERTILITY TESTING AND TREATMENT MARKET BY GENDER 2019-2027 ($ MILLION)
TABLE 2 AVERAGE COST COMPARISON OF INFERTILITY TREATMENTS
TABLE 3 EUROPE MALE INFERTILITY TESTING AND TREATMENT MARKET 2019-2027 ($ MILLION)
TABLE 4 EUROPE MALE INFERTILITY TESTING MARKET 2019-2027 ($ MILLION)
TABLE 5 PROS AND CONS OF DNA SHARING METHODS
TABLE 6 EUROPE FEMALE INFERTILITY TESTING AND TREATMENT MARKET 2019-2027 ($ MILLION)
TABLE 7 EUROPE FEMALE INFERTILITY TESTING MARKET 2019-2027 ($ MILLION)
TABLE 8 EUROPE FEMALE INFERTILITY TREATMENT MARKET 2019-2027 ($ MILLION)
TABLE 9 AVERAGE COST OF SOME INFERTILITY TREATMENTS
TABLE 10 SOME COMMON DRUG THERAPIES
TABLE 11 EUROPE INFERTILITY TESTING AND TREATMENT MARKET BY END-USERS 2019-2027 ($ MILLION)
TABLE 12 EUROPE INFERTILITY TESTING AND TREATMENT MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 13 COST OF IVF IN RUSSIA

List of Figures

LIST OF FIGURES
FIGURE 1 EUROPE INFERTILITY TESTING AND TREATMENT MARKET 2019-2027 ($ MILLION)
FIGURE 2 MAJOR FERTILITY TREATMENT DESTINATION RANKING
FIGURE 3 CLINICAL ALGORITHM FOR THE EVALUATION OF INFERTILE WOMAN
FIGURE 4 RATE OF MULTIPLE DELIVERIES
FIGURE 5 CAUSES OF INFERTILITY
FIGURE 6 CAUSES OF INFERTILITY BASED ON GENDER
FIGURE 7 CAUSES OF SPERM DNA FRAGMENTATION
FIGURE 8 UK INFERTILITY TESTING AND TREATMENT MARKET 2019-2027 ($ MILLION)
FIGURE 9 FERTILITY TREATMENT IN 2014
FIGURE 10 GERMANY INFERTILITY TESTING AND TREATMENT MARKET 2019-2027 ($ MILLION)
FIGURE 11 FRANCE INFERTILITY TESTING AND TREATMENT MARKET 2019-2027 ($ MILLION)
FIGURE 12 NORDICS INFERTILITY TESTING AND TREATMENT MARKET 2019-2027 ($ MILLION)
FIGURE 13 RUSSIA INFERTILITY TESTING AND TREATMENT MARKET 2019-2027 ($ MILLION)

 

COPYRIGHT(C) 2011-2020 DATA RESOURCES, Inc. ALL RIGHTS RESERVED.